Annual FCF
-$70.84 M
+$38.09 M+34.96%
31 December 2023
Summary:
Protagonist Therapeutics annual free cash flow is currently -$70.84 million, with the most recent change of +$38.09 million (+34.96%) on 31 December 2023. During the last 3 years, it has risen by +$38.12 million (+34.98%). PTGX annual FCF is now -2309.76% below its all-time high of $3.21 million, reached on 31 December 2017.PTGX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$28.64 M
-$297.23 M-110.66%
30 September 2024
Summary:
Protagonist Therapeutics quarterly free cash flow is currently -$28.64 million, with the most recent change of -$297.23 million (-110.66%) on 30 September 2024. Over the past year, it has dropped by -$45.58 million (-269.05%). PTGX quarterly FCF is now -110.66% below its all-time high of $268.59 million, reached on 30 June 2024.PTGX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$229.23 M
-$1.62 M-0.70%
30 September 2024
Summary:
Protagonist Therapeutics TTM free cash flow is currently $229.23 million, with the most recent change of -$1.62 million (-0.70%) on 30 September 2024. Over the past year, it has increased by +$300.07 million (+423.56%). PTGX TTM FCF is now -0.70% below its all-time high of $230.85 million, reached on 30 June 2024.PTGX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTGX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -269.1% | +423.6% |
| 3 y3 years | +35.0% | -5.5% | +310.4% |
| 5 y5 years | -66.7% | -97.4% | +639.4% |
PTGX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +35.0% | -110.7% | +24.5% | -0.7% | +291.8% |
| 5 y | 5 years | -66.7% | +35.0% | -110.7% | +24.5% | -0.7% | +291.8% |
| alltime | all time | -2309.8% | +35.0% | -110.7% | +24.5% | -0.7% | +291.8% |
Protagonist Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$28.64 M(-110.7%) | $229.23 M(-0.7%) |
| June 2024 | - | $268.59 M(-1070.7%) | $230.85 M(-459.8%) |
| Mar 2024 | - | -$27.67 M(-263.3%) | -$64.16 M(-9.4%) |
| Dec 2023 | -$70.84 M(-35.0%) | $16.94 M(-162.7%) | -$70.84 M(-40.7%) |
| Sept 2023 | - | -$27.02 M(+2.3%) | -$119.49 M(+1.4%) |
| June 2023 | - | -$26.41 M(-23.1%) | -$117.84 M(+11.9%) |
| Mar 2023 | - | -$34.36 M(+8.4%) | -$105.35 M(-3.3%) |
| Dec 2022 | -$108.93 M(-0.0%) | -$31.70 M(+25.0%) | -$108.93 M(+4.4%) |
| Sept 2022 | - | -$25.36 M(+82.1%) | -$104.36 M(-3.1%) |
| June 2022 | - | -$13.93 M(-63.3%) | -$107.73 M(-8.7%) |
| Mar 2022 | - | -$37.94 M(+39.8%) | -$118.01 M(+8.3%) |
| Dec 2021 | -$108.97 M(+49.4%) | -$27.14 M(-5.6%) | -$108.97 M(+8.1%) |
| Sept 2021 | - | -$28.73 M(+18.7%) | -$100.82 M(+14.0%) |
| June 2021 | - | -$24.20 M(-16.3%) | -$88.45 M(+3.0%) |
| Mar 2021 | - | -$28.90 M(+52.1%) | -$85.86 M(+17.7%) |
| Dec 2020 | -$72.95 M(+71.7%) | -$18.99 M(+16.1%) | -$72.95 M(+6.6%) |
| Sept 2020 | - | -$16.36 M(-24.3%) | -$68.47 M(+3.7%) |
| June 2020 | - | -$21.61 M(+35.2%) | -$66.05 M(+58.6%) |
| Mar 2020 | - | -$15.99 M(+10.2%) | -$41.65 M(-2.0%) |
| Dec 2019 | -$42.49 M | -$14.51 M(+4.1%) | -$42.49 M(+11.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$13.94 M(-601.7%) | -$38.18 M(+13.4%) |
| June 2019 | - | $2.78 M(-116.5%) | -$33.67 M(-35.1%) |
| Mar 2019 | - | -$16.83 M(+65.0%) | -$51.91 M(+2.9%) |
| Dec 2018 | -$50.43 M(-1673.1%) | -$10.20 M(+8.2%) | -$50.43 M(-7.4%) |
| Sept 2018 | - | -$9.42 M(-39.1%) | -$54.44 M(+1109.0%) |
| June 2018 | - | -$15.47 M(+0.8%) | -$4.50 M(+159.4%) |
| Mar 2018 | - | -$15.35 M(+8.0%) | -$1.74 M(-154.1%) |
| Dec 2017 | $3.21 M(-110.6%) | -$14.21 M(-135.1%) | $3.21 M(-58.2%) |
| Sept 2017 | - | $40.51 M(-419.0%) | $7.68 M(-119.3%) |
| June 2017 | - | -$12.70 M(+22.1%) | -$39.83 M(+13.1%) |
| Mar 2017 | - | -$10.40 M(+6.9%) | -$35.23 M(+16.2%) |
| Dec 2016 | -$30.32 M(+105.1%) | -$9.73 M(+39.1%) | -$30.32 M(+18.7%) |
| Sept 2016 | - | -$7.00 M(-13.6%) | -$25.55 M(+13.9%) |
| June 2016 | - | -$8.10 M(+47.6%) | -$22.43 M(+25.8%) |
| Mar 2016 | - | -$5.49 M(+10.7%) | -$17.84 M(+20.6%) |
| Dec 2015 | -$14.78 M(+83.8%) | -$4.96 M(+27.7%) | -$14.78 M(+50.5%) |
| Sept 2015 | - | -$3.88 M(+10.8%) | -$9.82 M(+65.3%) |
| June 2015 | - | -$3.50 M(+43.8%) | -$5.94 M(+143.8%) |
| Mar 2015 | - | -$2.44 M | -$2.44 M |
| Dec 2014 | -$8.04 M | - | - |
FAQ
- What is Protagonist Therapeutics annual free cash flow?
- What is the all time high annual FCF for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly FCF year-on-year change?
- What is Protagonist Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM FCF year-on-year change?
What is Protagonist Therapeutics annual free cash flow?
The current annual FCF of PTGX is -$70.84 M
What is the all time high annual FCF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual free cash flow is $3.21 M
What is Protagonist Therapeutics quarterly free cash flow?
The current quarterly FCF of PTGX is -$28.64 M
What is the all time high quarterly FCF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly free cash flow is $268.59 M
What is Protagonist Therapeutics quarterly FCF year-on-year change?
Over the past year, PTGX quarterly free cash flow has changed by -$45.58 M (-269.05%)
What is Protagonist Therapeutics TTM free cash flow?
The current TTM FCF of PTGX is $229.23 M
What is the all time high TTM FCF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM free cash flow is $230.85 M
What is Protagonist Therapeutics TTM FCF year-on-year change?
Over the past year, PTGX TTM free cash flow has changed by +$300.07 M (+423.56%)